Dr. Ikechukwu (Ike) Ogbu is a highly regarded Board-Certified Internal Medicine physician with extensive expertise in managing both acute and chronic medical conditions. His commitment to patient care extends beyond the clinical setting, as he also plays a crucial role in the hospital environment, where he oversees more urgent cases.
Dr. Ogbu’s board certification in Internal Medicine reflects his dedication to maintaining the highest standards of medical practice. This certification signifies that he has successfully completed rigorous training and examinations, demonstrating his proficiency in diagnosing, treating, and preventing a wide range of medical issues.
Dr. Ogbu’s experience spans the spectrum of medical care. Whether it’s a sudden illness or a long-standing health concern, he approaches each case with precision and empathy. From managing acute infections to addressing chronic diseases such as diabetes, hypertension, and autoimmune disorders, Dr. Ogbu tailors his treatment plans to meet the unique needs of each patient.
Dr. Ogbu’s involvement in the hospital setting allows him to tackle more urgent and complex cases. Here are some key aspects of his hospital-based work:
Hospitals often require interdisciplinary teamwork. Dr. Ogbu collaborates closely with specialists, surgeons, nurses, and other healthcare professionals to optimize patient outcomes. His holistic approach considers not only the immediate issue but also the patient’s overall well-being.
Regardless of the clinical context, Dr. Ogbu’s unwavering goal is to provide compassionate and comprehensive care. He understands that each patient is unique, with their own fears, hopes, and health challenges. By actively listening, communicating clearly, and showing empathy, Dr. Ogbu creates a healing environment where patients feel valued and understood.
Build an affordable and super simple healthcare system designed to restore health and enhance quality of life. We are dedicated to utilizing a combination of pharmaceutical, non-pharmaceutical, non-surgical, and non-invasive methods to provide comprehensive and precision care for all.
Make healthcare universally accessible, affordable, and personalized, catering to everyone—whether they have insurance, are out of network, or are uninsured. We are committed to inclusivity and ensuring that no one is left behind when it comes to receiving quality healthcare.
Provide accessible, high-quality healthcare for everyone, no matter where you are. We believe that healthcare should be simple, convenient, affordable, and compassionate.








Snoring Survivors: the impact of obstructive sleep apnea and continuous positive airway pressure use on in-hospital mortality, length of stay and costs among patients hospitalized with acute cardiovascular disease
Relationship between Cardiovascular Risk Factors and Composite Cardiovascular Outcomes in Patients Hospitalized with Takotsubo Syndrome: A Nationwide Analysis
Sleep-disordered breathing (SDB), which includes conditions such as obstructive sleep apnea (OSA) and central sleep apnea (CSA), is an independent risk factor for cerebral small vessel disease (CSVD), stroke, heart failure, arrhythmias, and other cardiovascular disorders.
Cardiac amyloidosis (CA) is a form of infiltrative, restrictive cardiomyopathy that presents a diagnostic and therapeutic challenge in clinical practice. Historically, it has led to poor prognosis due to limited treatment options.
Non-alcoholic fatty liver disease (NAFLD) increases cardiovascular disease (CVD) risk irrespective of other risk factors. However, large-scale cardiovascular sex and race differences are poorly understood.
Sleep disorders significantly contribute to cardiac arrhythmias. Mechanisms such as intermittent hypoxia, autonomic dysfunction, and intrathoracic pressure changes are central to this relationship. Strong evidence shows that severe Sleep breathing disorders substantially increases arrhythmia risk, while CPAP therapy effectively reduces this risk.
Inflammatory bowel disease (IBD) and dependent cannabis use or cannabis use disorder (CUD+) are independent risk factors for cardiovascular diseases. Usage of cannabis for pain increased in IBD patients. However, associated cardiovascular safety remains unclear. This study aims to investigate the major adverse cardiac and cerebrovascular events (MACCE) associated with CUD + in hospitalized IBD patients.
End-stage renal disease (ESRD) patients with more intensive renal replacement therapy have been shown to alleviate the severity of sleep apnea, specifically obstructive sleep apnea (OSA). Our study aims to analyze the trends in combined cardiovascular events among geriatric CKD patients, comparing those with and without OSA.
Glucagon-like peptide-1 (GLP-1) protects against ischemia-reperfusion injury in patients with heart attack. Controversy exists on the effects of GLP-1 on heart attack patients undergoing heart stent procedure or open heart surgery.
In 2018, a total of 30,259,863 hospitalizations were reported in the US, of which 30,335 had a diagnosis of IPF and 8,075 of pulmonary hypertension.
The late-breaking science presented at the 2023 scientific session of the American Heart Association paves the way for future pragmatic trials and provides meaningful information to guide management strategies in coronary artery disease and heart failure (HF).
Takotsubo cardiomyopathy (TTC) is characterized by transient myocardial dysfunction triggered by both negative and positive emotional experiences, known respectively as broken heart syndrome (BHS) and happy heart syndrome (HHS).